ZYMEZymeworks Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+72.6% YoY

Gross Profit

$28M100.0% margin

Operating Income

-$22M-80.1% margin

Net Income

-$20M-71.0% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-43.3%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$397M

Total Liabilities

$77M

Stockholders' Equity

$320M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$16M	+72.6%
Gross Profit	$28M	$16M	+72.6%
Operating Income	-$22M	-$34M	+35.4%
Net Income	-$20M	-$30M	+34.3%

Revenue Segments

Milestone Revenue

$25M95%

Royalty

$831,0003%

Research Support Payments And Other Service

$352,0001%

ZYME Q3 2025 Earnings — Zymeworks Inc. Revenue & Financial Results | Market Cap Arena